Mar 28, 2022 / 02:15PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thank you very much, everybody. It's my pleasure to be hosting Priya Singhal, Biogen's Interim Head of Research and Development, this morning. We'll have a lot to talk about as it relates to Alzheimer's, neuropsychiatry, antisense oligonucleotides and anything else Priya thinks that I'm overlooking here that definitely needs more attention.
Questions and Answers:
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior AnalystBut maybe we can start with conversation around Alzheimer's, Priya. And I assume there's not a ton you can say, but I'd be remiss at not at least asking for an update on where things stand ahead of the final NCD and if you think there's any sort of plausible path to materially modifying things as we get the final decision?
Priya Singhal - Biogen Inc. - Senior VP, Head of Global Safety
Trustpilot
